posted on 2021-10-06, 04:00authored byFernando Fernández-Bañares, Natalia López-Palacios, María Corzo, Beatriz Arau, Mercedes Rubio, Marta Fernández-Prieto, Eva Tristán, Mar Pujals, Sergio Farrais, Saúl Horta, Juana María Hernández, Marta Gomez-Perosanz, Pedro A. Reche, María Esteve, Concepción Núñez
Additional file 3. Supplementary materials: Materials S2. IFN-γ ELISPOT (enzyme-linked immunospot) assay. Materials S3. Additional methods: Histological analysis. Intraepithelial lymphogram. Supplementary results: Table S1. Median (IQR) of the studied CD8+ (percentage at day 6 and ratio day 6/day 0) and TCRγδ+ (percentage at day 6) T cell populations in the different groups of participants (in bold) and adjusted p values of the comparisons between groups obtained using a Dunn’s test following a significant Kruskal-Wallis test. Table S2. Global VAS score and VAS of individual clinical symptoms reported by the participants during the six days of the study (mean intensity ± SE and number and percentage of patients reporting the symptom).
Funding
Instituto de Salud Carlos III Federación de Asociaciones de Celiacos de España (FACE)